DK2096120T3 - Anvendelse af sekreterede proteinprodukter til at forebygge og behandle pankreatiske sygdomme og/eller obesitet og/eller metabolsk syndrom - Google Patents

Anvendelse af sekreterede proteinprodukter til at forebygge og behandle pankreatiske sygdomme og/eller obesitet og/eller metabolsk syndrom

Info

Publication number
DK2096120T3
DK2096120T3 DK09163270.3T DK09163270T DK2096120T3 DK 2096120 T3 DK2096120 T3 DK 2096120T3 DK 09163270 T DK09163270 T DK 09163270T DK 2096120 T3 DK2096120 T3 DK 2096120T3
Authority
DK
Denmark
Prior art keywords
obesity
metabolic syndrome
prevent
secreted protein
protein products
Prior art date
Application number
DK09163270.3T
Other languages
English (en)
Inventor
Daria Onichtchouk
Original Assignee
Develogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen Ag filed Critical Develogen Ag
Application granted granted Critical
Publication of DK2096120T3 publication Critical patent/DK2096120T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK09163270.3T 2004-02-20 2005-02-18 Anvendelse af sekreterede proteinprodukter til at forebygge og behandle pankreatiske sygdomme og/eller obesitet og/eller metabolsk syndrom DK2096120T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04003914 2004-02-20
EP05701416A EP1730189A2 (en) 2004-02-20 2005-02-18 Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome

Publications (1)

Publication Number Publication Date
DK2096120T3 true DK2096120T3 (da) 2012-07-09

Family

ID=34878165

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09163270.3T DK2096120T3 (da) 2004-02-20 2005-02-18 Anvendelse af sekreterede proteinprodukter til at forebygge og behandle pankreatiske sygdomme og/eller obesitet og/eller metabolsk syndrom

Country Status (6)

Country Link
US (2) US20070248579A1 (da)
EP (2) EP2096120B1 (da)
AT (1) ATE549352T1 (da)
DK (1) DK2096120T3 (da)
ES (1) ES2384134T3 (da)
WO (1) WO2005079840A2 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092214A1 (en) * 2007-02-02 2008-08-07 Minomic International Limited Biomarkers for diabetes
WO2013102209A1 (en) * 2011-12-30 2013-07-04 Joslin Diabetes Center, Inc. Glypican-4 based compositions and methods for treating and diagnosing insulin resistance
CN103113468B (zh) * 2013-01-17 2014-05-21 中国人民解放军军事医学科学院基础医学研究所 一种抗肿瘤蛋白质
KR102065150B1 (ko) 2018-04-27 2020-01-10 (주)케어젠 이소트레티노인-펩타이드 결합체를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
CA3174478A1 (en) 2020-03-05 2021-09-10 DiaMedica USA Inc. Ulinastatin polypeptides
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5605662A (en) 1993-11-01 1997-02-25 Nanogen, Inc. Active programmable electronic devices for molecular biological analysis and diagnostics
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5886029A (en) * 1997-09-05 1999-03-23 Dhaliwal; Kirpal S. Method and composition for treatment of diabetes
WO2001000672A1 (en) * 1999-06-29 2001-01-04 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US20030170781A1 (en) * 1999-07-01 2003-09-11 Zymogenetics, Inc. Secreted protein zacrp4
CA2433313A1 (en) * 2000-12-19 2002-07-25 Curagen Corporation Polypetides and nucleic acids encoding same
US20040248156A1 (en) * 2001-12-03 2004-12-09 Tianhua Hu Methods and materials relating to novel C1q domain-containing polypeptides and polynucleotides
WO2003077939A1 (en) * 2002-03-19 2003-09-25 Genset Sa Treatment of metabolic disorders with a tnf receptor family member (fradj and/or cryptic) agonists or antagonists

Also Published As

Publication number Publication date
EP2096120A2 (en) 2009-09-02
US20090298771A1 (en) 2009-12-03
EP1730189A2 (en) 2006-12-13
ES2384134T3 (es) 2012-06-29
WO2005079840A2 (en) 2005-09-01
EP2096120A3 (en) 2009-12-02
WO2005079840A3 (en) 2006-10-26
ATE549352T1 (de) 2012-03-15
US20070248579A1 (en) 2007-10-25
EP2096120B1 (en) 2012-03-14

Similar Documents

Publication Publication Date Title
NL301089I2 (nl) imlifidase
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
NO20082790L (no) Behandling av type 2 diabetes med en kombinasjon av DPIV inhibitor og metformin eller thiazolidindion
NO20092034L (no) Kjemiske forbindelser og anvendelser
DE602006007093D1 (de) Kombinationstherapie zur Behandlung von Diabetes und dadurch bedingten Leiden sowie zur Behandlung von mittels Erhöhung des GLP-1-Spiegels im Blut verbesserten Leiden
WO2003101401A3 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
WO2007146425A3 (en) Compounds and methods for treatment of chemotherapy-induced anemia
WO2008054540A3 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
EA201190054A1 (ru) Аналоги глюкагона
EA201190049A1 (ru) Аналоги глюкагона
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
NO20072223L (no) Glykogenfosforylaseinhibitor forbindelser med farmsoytiske preparater av disse
EA201001322A1 (ru) Вакцины против хламидиоза
CY1112620T1 (el) Συνθεσεις οι οποιες περιλαμβανουν πεπτιδια βασικης πρωτεϊνης της μυελινης και ιατρικες χρησεις αυτων
DK2096120T3 (da) Anvendelse af sekreterede proteinprodukter til at forebygge og behandle pankreatiske sygdomme og/eller obesitet og/eller metabolsk syndrom
DK1771426T3 (da) Diphenylaminsubstituererede salicylthiazolderivater og beslægtede forbindelser som phosphotyrosinphosphatase 1B (PTP1B) hæmmer til anvendelse som blodsukkersænkende aktive stoffer til behandling af diabetes
NO20075695L (no) Fremgangsmate til a behandle eller forhindre type-2 diabetes
DE60115349D1 (de) Polymorphismen im Gen für den humanen organischen Anionentransporter C (OATP-C)
DE602008004556D1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
WO2006046073A3 (en) C1q related protein
WO2005053728A3 (de) Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik
WO2005005471A3 (en) Use of dg153 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
WO2007139970A3 (en) Men1 gene for diagnosis and treatment of diabetes
DK1605965T3 (da) Anvendelse af saposin-beslægtede proteiner til forebyggelse og behandling af obesitet, diabetes og/eller metabolisk syndrom
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit